title: Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.
abstract: In the May 26th issue of the New England Journal of Medicine, de Bono et al. report that the inhibition of androgen synthesis by abiraterone acetate prolonged the survival of men with prostate cancer previously treated by androgen suppression.
authors: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231-1000, USA. bnelson@jhmi.edu
authors: William G
authors: WG
authors: Nelson
authors: Michael C
authors: MC
authors: Haffner
authors: Srinivasan
authors: S
authors: Yegnasubramanian